DK3338791T3 - Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt - Google Patents

Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt Download PDF

Info

Publication number
DK3338791T3
DK3338791T3 DK17209369.2T DK17209369T DK3338791T3 DK 3338791 T3 DK3338791 T3 DK 3338791T3 DK 17209369 T DK17209369 T DK 17209369T DK 3338791 T3 DK3338791 T3 DK 3338791T3
Authority
DK
Denmark
Prior art keywords
neureguline
prophylaxis
treatment
heart failure
therapeutic dosage
Prior art date
Application number
DK17209369.2T
Other languages
Danish (da)
English (en)
Inventor
Anthony Caggiano
Anindita Ganguly
Jennifer Iaci
Tom Parry
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of DK3338791T3 publication Critical patent/DK3338791T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK17209369.2T 2008-07-17 2009-07-17 Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt DK3338791T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
EP09813336.6A EP2320933B1 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
DK3338791T3 true DK3338791T3 (da) 2019-12-16

Family

ID=42005671

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17209369.2T DK3338791T3 (da) 2008-07-17 2009-07-17 Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt
DK09813336.6T DK2320933T3 (en) 2008-07-17 2009-07-17 THERAPEUTIC DOSAGE OF A NEUREGULIN OR A SUBSEQUENT THEREOF FOR TREATMENT OR PROPHYLAXY OF HEART FAILURE

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09813336.6T DK2320933T3 (en) 2008-07-17 2009-07-17 THERAPEUTIC DOSAGE OF A NEUREGULIN OR A SUBSEQUENT THEREOF FOR TREATMENT OR PROPHYLAXY OF HEART FAILURE

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP2320933B1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN107019794B (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK3338791T3 (enExample)
ES (2) ES2664394T3 (enExample)
MX (2) MX384378B (enExample)
PL (2) PL3338791T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP2328606B1 (en) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
EP2808339B1 (en) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
BR112012008821A2 (pt) 2009-10-14 2020-09-15 Acorda Therapeutics, Inc. uso de neuregulina para tratar lesões nervosas periféricas.
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN104321072A (zh) * 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP2999499B1 (en) 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CA2999301A1 (en) 2015-09-25 2017-03-30 Douglas B. Sawyer Methods for treating cardiac injury
WO2017182500A1 (en) * 2016-04-19 2017-10-26 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Neuregulin for the treatment and/or prevention of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US20230057622A1 (en) * 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
DK1115417T3 (da) 1998-09-25 2006-07-31 Cubist Pharm Inc Anvendelse af daptomycin
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
CA2388918A1 (en) 1999-11-12 2001-05-17 Entremed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
ES2610353T3 (es) 2000-05-23 2017-04-27 Cenes Pharmaceuticals, Inc. Moléculas de ácido nucleico NRG-2, polipéptidos y métodos diagnósticos y terapéuticos
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1569689A4 (en) 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2008530186A (ja) * 2005-02-18 2008-08-07 オリオン コーポレーション 心不全治療法
BRPI0609427A2 (pt) 2005-03-23 2010-04-06 Pfizer Prod Inc composição farmacêutica para o tratamento de cáncer de próstata e uso de um agente de terapia hormonal e de um anticorpo, ou uma porção de ligação a antìgeno do mesmo
WO2007028085A2 (en) 2005-09-02 2007-03-08 Morehouse School Of Medicine Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) * 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
US8410050B2 (en) 2008-02-29 2013-04-02 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
US20110166068A1 (en) * 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
BR112012008821A2 (pt) 2009-10-14 2020-09-15 Acorda Therapeutics, Inc. uso de neuregulina para tratar lesões nervosas periféricas.
CA2845198A1 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
CN104321072A (zh) 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用

Also Published As

Publication number Publication date
US9956266B2 (en) 2018-05-01
AU2009292216A1 (en) 2010-03-18
AU2009292216B2 (en) 2015-03-05
EP2320933B1 (en) 2017-12-27
PL2320933T3 (pl) 2018-07-31
RU2719199C1 (ru) 2020-04-17
RU2536938C2 (ru) 2014-12-27
CA2731113A1 (en) 2010-03-18
AU2015202877A1 (en) 2015-06-18
AU2017203528A1 (en) 2017-06-15
EP3632459A1 (en) 2020-04-08
CN107019794A (zh) 2017-08-08
PL3338791T3 (pl) 2020-04-30
JP2017200949A (ja) 2017-11-09
ES2763184T3 (es) 2020-05-27
US11235031B2 (en) 2022-02-01
RU2011105821A (ru) 2012-08-27
RU2020111236A (ru) 2021-09-21
CN104623633A (zh) 2015-05-20
US9198951B2 (en) 2015-12-01
BRPI0916442A2 (pt) 2018-06-19
US20200009228A1 (en) 2020-01-09
MX2011000696A (es) 2011-07-29
RU2014141514A (ru) 2016-05-10
JP5797112B2 (ja) 2015-10-21
EP3338791B1 (en) 2019-09-18
EP2320933A1 (en) 2011-05-18
US20160113999A1 (en) 2016-04-28
CN107019794B (zh) 2021-03-12
CN102159236A (zh) 2011-08-17
JP2019196370A (ja) 2019-11-14
RU2020111236A3 (enExample) 2021-09-21
DK2320933T3 (en) 2018-04-16
ES2664394T3 (es) 2018-04-19
EP2320933A4 (en) 2013-02-27
MX384378B (es) 2025-03-14
US20110166068A1 (en) 2011-07-07
JP2015129137A (ja) 2015-07-16
WO2010030317A2 (en) 2010-03-18
US20130324466A1 (en) 2013-12-05
RU2698090C2 (ru) 2019-08-22
JP2011528353A (ja) 2011-11-17
JP2022023208A (ja) 2022-02-07
AU2015202877B2 (en) 2017-03-09
EP3338791A1 (en) 2018-06-27
JP6189879B2 (ja) 2017-08-30
US20180280477A1 (en) 2018-10-04
HK1256637A1 (en) 2019-09-27

Similar Documents

Publication Publication Date Title
FR18C1043I2 (fr) Therapie antivirale
PL3338791T3 (pl) Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
DK2448637T4 (da) Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi
DK2222272T3 (da) Behandling af luftvejssygdom
NO2019010I1 (no) Eravasyklin eller farmasøytisk akseptable salter derav
CY2014006I1 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
LT2782584T (lt) Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
DK2488242T3 (da) Medicinsk indåndingsmaske
RU2557654C3 (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
DK3967274T3 (da) Hjerteklapanordninger med stent
BRPI1011441A2 (pt) cinta corporal terapeutica
HRP20170972T1 (hr) Kombinacijska terapija afukoziliranog cd20-protutijela s bendamustinom
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
BRPI0912559A2 (pt) método de tratar insuficiência cardíaca crônica
IL233313A0 (en) Composition of novel carbohydrate drug for treatment of human diseases
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
BRPI0907950A2 (pt) Tratamento de hiperglicemia com 25-hidroxivitamina d3
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
ZA201308391B (en) Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
FI20096402A0 (fi) Veriryhmästatuksen käyttö II
DK2323686T3 (da) Adiponectin til behandling af lungesygdom
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BRPI1009322A2 (pt) dose de ave5026 para o tratamento de tromboembolia venosa em pacientes com deficiência renal grave
EP2350264A4 (en) TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT